Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 528 entries
Sorted by: Best Match Show Resources per page
Correction.

The Lancet. Infectious diseases

[No authors listed]
PMID: 26122437
Lancet Infect Dis. 2015 Jul;15(7):761. doi: 10.1016/S1473-3099(15)00090-0. Epub 2015 Jun 03.

ENCORE1 Study Group. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 2015; published online April 13. http://dx.doi.org/10.1016/S1473- 3099(15)70060-5—In this Article, the numbers...

Cite
Correction. Lancet Infect Dis. 2015;15(7):761doi: 10.1016/S1473-3099(15)00090-0.
(2015). Correction. The Lancet. Infectious diseases, 15(7), 761. https://doi.org/10.1016/S1473-3099(15)00090-0
"Correction." The Lancet. Infectious diseases vol. 15,7 (2015): 761. doi: https://doi.org/10.1016/S1473-3099(15)00090-0
Correction. Lancet Infect Dis. 2015 Jul;15(7):761. doi: 10.1016/S1473-3099(15)00090-0. Epub 2015 Jun 03. PMID: 26122437.
Copy Download .nbib Format: NLM
[Not Available].

Therapie

Solas C, Gagnieu MC.
PMID: 27393199
Therapie. 2011 May-Jun;66(3):197-205. doi: 10.2515/therapie/2011033.

The efavirenz, a non nucleoside reverse transcriptase inhibitor of HIV-1, presents a marked pharmacokinetics variability related to an intense hepatic metabolism. Efavirenz is also a potent inducer. Central nervous system (CNS) toxicity associated with efavirenz therapy is a major...

Cite
Solas C, Gagnieu MC. Niveau de preuve du suivi thérapeutique pharmacologique de l'efavirenz. [Not Available]. Therapie. 2011;66(3):197-205doi: 10.2515/therapie/2011033.
Solas, C., Gagnieu, M. C. (2011). Niveau de preuve du suivi thérapeutique pharmacologique de l'efavirenz. [Not Available]. Therapie, 66(3), 197-205. https://doi.org/10.2515/therapie/2011033
Solas, Caroline, et al. "Niveau de preuve du suivi thérapeutique pharmacologique de l'efavirenz." [Not Available]. Therapie vol. 66,3 (2011): 197-205. doi: https://doi.org/10.2515/therapie/2011033
Solas C, Gagnieu MC. Niveau de preuve du suivi thérapeutique pharmacologique de l'efavirenz. [Not Available]. Therapie. 2011 May-Jun;66(3):197-205. doi: 10.2515/therapie/2011033. French. PMID: 27393199.
Copy Download .nbib Format: NLM
Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy.

F1000Research

Kakande B, Isaacs T, Muloiwa R, Dlamini S, Lehloenya R.
PMID: 26629333
F1000Res. 2015 Jun 30;4:175. doi: 10.12688/f1000research.6715.1. eCollection 2015.

A 31-year old HIV-infected African woman on nevirapine, tenofovir and lamivudine for more than 4 years presented with an 8-day history of symptoms and signs of Stevens-Johnson syndrome. She was on no other medication. Her viral load was undetectable...

Cite
Kakande B, Isaacs T, Muloiwa R, et al. Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy. F1000Res. 2015;4:175doi: 10.12688/f1000research.6715.1.
Kakande, B., Isaacs, T., Muloiwa, R., Dlamini, S., & Lehloenya, R. (2015). Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy. F1000Research, 4175. https://doi.org/10.12688/f1000research.6715.1
Kakande, Betty, et al. "Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy." F1000Research vol. 4 (2015): 175. doi: https://doi.org/10.12688/f1000research.6715.1
Kakande B, Isaacs T, Muloiwa R, Dlamini S, Lehloenya R. Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy. F1000Res. 2015 Jun 30;4:175. doi: 10.12688/f1000research.6715.1. eCollection 2015. PMID: 26629333; PMCID: PMC4642844.
Copy Download .nbib Format: NLM
Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy.

Therapeutics and clinical risk management

Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q.
PMID: 25848291
Ther Clin Risk Manag. 2015 Mar 19;11:449-67. doi: 10.2147/TCRM.S80437. eCollection 2015.

BACKGROUND: Coprescribing of clopidogrel and other drugs is common. Available reviews have addressed the drug-drug interactions (DDIs) when clopidogrel is as an object drug, or focused on combination use of clopidogrel and a special class of drugs. Clinicians may...

Cite
Wang ZY, Chen M, Zhu LL, et al. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015;11:449-67doi: 10.2147/TCRM.S80437.
Wang, Z. Y., Chen, M., Zhu, L. L., Yu, L. S., Zeng, S., Xiang, M. X., & Zhou, Q. (2015). Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Therapeutics and clinical risk management, 11449-67. https://doi.org/10.2147/TCRM.S80437
Wang, Zhi-Yu, et al. "Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy." Therapeutics and clinical risk management vol. 11 (2015): 449-67. doi: https://doi.org/10.2147/TCRM.S80437
Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 2015 Mar 19;11:449-67. doi: 10.2147/TCRM.S80437. eCollection 2015. PMID: 25848291; PMCID: PMC4373598.
Copy Download .nbib Format: NLM
Complete dataset for 2-treatment, 2-sequence, 2-period efavirenz bioequivalence study conducted with nightly dosing.

Data in brief

Ibarra M, Magallanes L, Lorier M, Vázquez M, Fagiolino P.
PMID: 27054190
Data Brief. 2016 Mar 15;7:751-4. doi: 10.1016/j.dib.2016.03.036. eCollection 2016 Jun.

The efavirenz pharmacokinetic raw data presented in this article was obtained in an average bioequivalence study between a local brand and Stocrin (Merck Sharp & Dohme, purchased from Australia, batch H009175, expiration date November 2013). Dose was administered at...

Cite
Ibarra M, Magallanes L, Lorier M, et al. Complete dataset for 2-treatment, 2-sequence, 2-period efavirenz bioequivalence study conducted with nightly dosing. Data Brief. 2016;7:751-4doi: 10.1016/j.dib.2016.03.036.
Ibarra, M., Magallanes, L., Lorier, M., Vázquez, M., & Fagiolino, P. (2016). Complete dataset for 2-treatment, 2-sequence, 2-period efavirenz bioequivalence study conducted with nightly dosing. Data in brief, 7751-4. https://doi.org/10.1016/j.dib.2016.03.036
Ibarra, Manuel, et al. "Complete dataset for 2-treatment, 2-sequence, 2-period efavirenz bioequivalence study conducted with nightly dosing." Data in brief vol. 7 (2016): 751-4. doi: https://doi.org/10.1016/j.dib.2016.03.036
Ibarra M, Magallanes L, Lorier M, Vázquez M, Fagiolino P. Complete dataset for 2-treatment, 2-sequence, 2-period efavirenz bioequivalence study conducted with nightly dosing. Data Brief. 2016 Mar 15;7:751-4. doi: 10.1016/j.dib.2016.03.036. eCollection 2016 Jun. PMID: 27054190; PMCID: PMC4804224.
Copy Download .nbib Format: NLM
Efavirenz as a cause of ataxia in children.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde

Hauptfleisch MP, Moore DP, Rodda JL.
PMID: 26636156
S Afr Med J. 2015 Oct;105(10):876. doi: 10.7196/samjnew.8780.

Acute ataxia in childhood is often caused by toxin ingestion. With the increasing number of paediatric patients on antiretroviral medication, we observe more side-effects of these drugs. Acute ataxia is defined as unsteadiness of walking or fine motor movement...

Cite
Hauptfleisch MP, Moore DP, Rodda JL. Efavirenz as a cause of ataxia in children. S Afr Med J. 2015;105(10):876doi: 10.7196/samjnew.8780.
Hauptfleisch, M. P., Moore, D. P., & Rodda, J. L. (2015). Efavirenz as a cause of ataxia in children. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 105(10), 876. https://doi.org/10.7196/samjnew.8780
Hauptfleisch, M P K, et al. "Efavirenz as a cause of ataxia in children." South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde vol. 105,10 (2015): 876. doi: https://doi.org/10.7196/samjnew.8780
Hauptfleisch MP, Moore DP, Rodda JL. Efavirenz as a cause of ataxia in children. S Afr Med J. 2015 Oct;105(10):876. doi: 10.7196/samjnew.8780. PMID: 26636156.
Copy Download .nbib Format: NLM
Modeling transportation of efavirenz: inference on possibility of mixed modes of transportation and kinetic solubility.

Frontiers in pharmacology

Nemaura T.
PMID: 26106329
Front Pharmacol. 2015 Jun 08;6:121. doi: 10.3389/fphar.2015.00121. eCollection 2015.

Understanding drug transportation mechanisms in the human body is of paramount importance in modeling Pharmacokinetic-Pharmacodynamic relationships. This work gives a novel general model of efavirenz transportation projections based on concentrations simulated from patients on a dose of 600 mg....

Cite
Nemaura T. Modeling transportation of efavirenz: inference on possibility of mixed modes of transportation and kinetic solubility. Front Pharmacol. 2015;6:121doi: 10.3389/fphar.2015.00121.
Nemaura, T. (2015). Modeling transportation of efavirenz: inference on possibility of mixed modes of transportation and kinetic solubility. Frontiers in pharmacology, 6121. https://doi.org/10.3389/fphar.2015.00121
Nemaura, Tafireyi. "Modeling transportation of efavirenz: inference on possibility of mixed modes of transportation and kinetic solubility." Frontiers in pharmacology vol. 6 (2015): 121. doi: https://doi.org/10.3389/fphar.2015.00121
Nemaura T. Modeling transportation of efavirenz: inference on possibility of mixed modes of transportation and kinetic solubility. Front Pharmacol. 2015 Jun 08;6:121. doi: 10.3389/fphar.2015.00121. eCollection 2015. PMID: 26106329; PMCID: PMC4458577.
Copy Download .nbib Format: NLM
The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection.

Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences

Wu L, Jin C, Bai S, Davies H, Rao H, Liang Y, Wu N.
PMID: 25983763
J Res Med Sci. 2015 Feb;20(2):127-32.

BACKGROUND: Co-infection of hepatitis virus is common in human immunodeficiency virus (HIV) infected adults in China. But little is known about hepatitis virus co-infection in pediatric HIV-infected subjects. The study aimed to investigate the impact of hepatitis B virus...

Cite
Wu L, Jin C, Bai S, et al. The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection. J Res Med Sci. 2015;20(2):127-32
Wu, L., Jin, C., Bai, S., Davies, H., Rao, H., Liang, Y., & Wu, N. (2015). The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 20(2), 127-32.
Wu, Lijuan, et al. "The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection." Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences vol. 20,2 (2015): 127-32.
Wu L, Jin C, Bai S, Davies H, Rao H, Liang Y, Wu N. The effect of highly active antiretroviral therapy on liver function in human immunodeficiency virus-infected pediatric patients with or without hepatitis virus co-infection. J Res Med Sci. 2015 Feb;20(2):127-32. PMID: 25983763; PMCID: PMC4400705.
Copy Download .nbib Format: NLM
A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.

Pharmacogenomics and personalized medicine

Damronglerd P, Sukasem C, Thipmontree W, Puangpetch A, Kiertiburanakul S.
PMID: 26622191
Pharmgenomics Pers Med. 2015 Oct 03;8:155-62. doi: 10.2147/PGPM.S86446. eCollection 2015.

OBJECTIVE: We aimed at comparing clinical/immunological outcomes in human immunodeficiency virus (HIV)-infected patients who were treated with CYP2B6-guided and conventional efavirenz (EFV) therapy.METHODS: This study was a 24-week prospective randomized controlled trial. Eligible patients were HIV-infected adults yet to...

Cite
Damronglerd P, Sukasem C, Thipmontree W, et al. A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study. Pharmgenomics Pers Med. 2015;8:155-62doi: 10.2147/PGPM.S86446.
Damronglerd, P., Sukasem, C., Thipmontree, W., Puangpetch, A., & Kiertiburanakul, S. (2015). A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study. Pharmacogenomics and personalized medicine, 8155-62. https://doi.org/10.2147/PGPM.S86446
Damronglerd, Pansachee, et al. "A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study." Pharmacogenomics and personalized medicine vol. 8 (2015): 155-62. doi: https://doi.org/10.2147/PGPM.S86446
Damronglerd P, Sukasem C, Thipmontree W, Puangpetch A, Kiertiburanakul S. A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study. Pharmgenomics Pers Med. 2015 Oct 03;8:155-62. doi: 10.2147/PGPM.S86446. eCollection 2015. PMID: 26622191; PMCID: PMC4638311.
Copy Download .nbib Format: NLM
Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics.

World journal of virology

Asensi V, Collazos J, Valle-Garay E.
PMID: 26279978
World J Virol. 2015 Aug 12;4(3):169-77. doi: 10.5501/wjv.v4.i3.169.

Pharmacogenetics refers to the effect of single nucleotide polymorphisms (SNPs) within human genes on drug therapy outcome. Its study might help clinicians to increase the efficacy of antiretroviral drugs by improving their pharmacokinetics and pharmacodynamics and by decreasing their...

Cite
Asensi V, Collazos J, Valle-Garay E. Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics. World J Virol. 2015;4(3):169-77doi: 10.5501/wjv.v4.i3.169.
Asensi, V., Collazos, J., & Valle-Garay, E. (2015). Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics. World journal of virology, 4(3), 169-77. https://doi.org/10.5501/wjv.v4.i3.169
Asensi, Victor, et al. "Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics." World journal of virology vol. 4,3 (2015): 169-77. doi: https://doi.org/10.5501/wjv.v4.i3.169
Asensi V, Collazos J, Valle-Garay E. Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics. World J Virol. 2015 Aug 12;4(3):169-77. doi: 10.5501/wjv.v4.i3.169. PMID: 26279978; PMCID: PMC4534808.
Copy Download .nbib Format: NLM
Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions.

Frontiers in pharmacology

Arimany-Nardi C, Minuesa G, Keller T, Erkizia I, Koepsell H, Martinez-Picado J, Pastor-Anglada M.
PMID: 27445813
Front Pharmacol. 2016 Jun 24;7:175. doi: 10.3389/fphar.2016.00175. eCollection 2016.

Lamivudine (3TC), a drug used in the treatment of HIV infection, needs to cross the plasma membrane to exert its therapeutic action. Human Organic cation transporter 1 (hOCT1), encoded by the SLC22A1 gene, is the transporter responsible for its...

Cite
Arimany-Nardi C, Minuesa G, Keller T, et al. Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. Front Pharmacol. 2016;7:175doi: 10.3389/fphar.2016.00175.
Arimany-Nardi, C., Minuesa, G., Keller, T., Erkizia, I., Koepsell, H., Martinez-Picado, J., & Pastor-Anglada, M. (2016). Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. Frontiers in pharmacology, 7175. https://doi.org/10.3389/fphar.2016.00175
Arimany-Nardi, Cristina, et al. "Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions." Frontiers in pharmacology vol. 7 (2016): 175. doi: https://doi.org/10.3389/fphar.2016.00175
Arimany-Nardi C, Minuesa G, Keller T, Erkizia I, Koepsell H, Martinez-Picado J, Pastor-Anglada M. Role of Human Organic Cation Transporter 1 (hOCT1) Polymorphisms in Lamivudine (3TC) Uptake and Drug-Drug Interactions. Front Pharmacol. 2016 Jun 24;7:175. doi: 10.3389/fphar.2016.00175. eCollection 2016. PMID: 27445813; PMCID: PMC4919327.
Copy Download .nbib Format: NLM
Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?.

Open access emergency medicine : OAEM

Kalsi SS, Wood DM, Waring WS, Dargan PI.
PMID: 27147854
Open Access Emerg Med. 2011 Oct 13;3:69-76. doi: 10.2147/OAEM.S24962. eCollection 2011.

Paracetamol (acetaminophen, N-acetyl-p-aminophenol, 4-hydroxyacetanilide) is the most common cause of acute liver failure in developed countries. There are a number of factors which potentially impact on the risk of an individual developing hepatotoxicity following an acute paracetamol overdose. These...

Cite
Kalsi SS, Wood DM, Waring WS, et al. Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?. Open Access Emerg Med. 2011;3:69-76doi: 10.2147/OAEM.S24962.
Kalsi, S. S., Wood, D. M., Waring, W. S., & Dargan, P. I. (2011). Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?. Open access emergency medicine : OAEM, 369-76. https://doi.org/10.2147/OAEM.S24962
Kalsi, Sarbjeet S, et al. "Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?." Open access emergency medicine : OAEM vol. 3 (2011): 69-76. doi: https://doi.org/10.2147/OAEM.S24962
Kalsi SS, Wood DM, Waring WS, Dargan PI. Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?. Open Access Emerg Med. 2011 Oct 13;3:69-76. doi: 10.2147/OAEM.S24962. eCollection 2011. PMID: 27147854; PMCID: PMC4753969.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 528 entries